NGM621

Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Fierce Biotech
Wed, 12/21/22 - 11:29 am
Merck
NGM Biopharmaceuticals
clinical trials
eye disease
NGM621
geographic atrophy